223 related articles for article (PubMed ID: 34635775)
1. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.
Das S; Idate R; Regan DP; Fowles JS; Lana SE; Thamm DH; Gustafson DL; Duval DL
Commun Biol; 2021 Oct; 4(1):1178. PubMed ID: 34635775
[TBL] [Abstract][Full Text] [Related]
2. TP53 gene mutations in canine osteosarcoma.
Kirpensteijn J; Kik M; Teske E; Rutteman GR
Vet Surg; 2008 Jul; 37(5):454-60. PubMed ID: 18986312
[TBL] [Abstract][Full Text] [Related]
3. HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.
Dailey DD; Anfinsen KP; Pfaff LE; Ehrhart EJ; Charles JB; Bønsdorff TB; Thamm DH; Powers BE; Jonasdottir TJ; Duval DL
BMC Vet Res; 2013 Jul; 9():130. PubMed ID: 23816051
[TBL] [Abstract][Full Text] [Related]
4.
Sakthikumar S; Elvers I; Kim J; Arendt ML; Thomas R; Turner-Maier J; Swofford R; Johnson J; Schumacher SE; Alföldi J; Axelsson E; Couto CG; Kisseberth WC; Pettersson ME; Getz G; Meadows JRS; Modiano JF; Breen M; Kierczak M; Forsberg-Nilsson K; Marinescu VD; Lindblad-Toh K
Cancer Res; 2018 Jul; 78(13):3421-3431. PubMed ID: 29724721
[TBL] [Abstract][Full Text] [Related]
5. P53 gene mutations in osteosarcomas in the dog.
van Leeuwen IS; Cornelisse CJ; Misdorp W; Goedegebuure SA; Kirpensteijn J; Rutteman GR
Cancer Lett; 1997 Jan; 111(1-2):173-8. PubMed ID: 9022143
[TBL] [Abstract][Full Text] [Related]
6. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
7. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
Mendoza S; Konishi T; Dernell WS; Withrow SJ; Miller CW
Anticancer Res; 1998; 18(6A):4449-53. PubMed ID: 9891508
[TBL] [Abstract][Full Text] [Related]
8. The immunotherapy of canine osteosarcoma: a historical and systematic review.
Wycislo KL; Fan TM
J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
[TBL] [Abstract][Full Text] [Related]
9. Pre- and postoperative studies of in vitro cell-mediated reactivity in canine osteosarcoma.
Bech-Nielsen S; Reif JS; Brodey RS
Am J Vet Res; 1978 Jan; 39(1):87-93. PubMed ID: 272858
[No Abstract] [Full Text] [Related]
10. Canine osteosarcoma genome sequencing identifies recurrent mutations in
Gardner HL; Sivaprakasam K; Briones N; Zismann V; Perdigones N; Drenner K; Facista S; Richholt R; Liang W; Aldrich J; Trent JM; Shields PG; Robinson N; Johnson J; Lana S; Houghton P; Fenger J; Lorch G; Janeway KA; London CA; Hendricks WPD
Commun Biol; 2019; 2():266. PubMed ID: 31341965
[TBL] [Abstract][Full Text] [Related]
11. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.
Angstadt AY; Motsinger-Reif A; Thomas R; Kisseberth WC; Guillermo Couto C; Duval DL; Nielsen DM; Modiano JF; Breen M
Genes Chromosomes Cancer; 2011 Nov; 50(11):859-74. PubMed ID: 21837709
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the chaotic genomic landscape of primary and metastatic canine appendicular osteosarcoma with current sequencing technologies and bioinformatic approaches.
Chu S; Skidmore ZL; Kunisaki J; Walker JR; Griffith M; Griffith OL; Bryan JN
PLoS One; 2021; 16(2):e0246443. PubMed ID: 33556121
[TBL] [Abstract][Full Text] [Related]
13. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.
Fenger JM; London CA; Kisseberth WC
ILAR J; 2014; 55(1):69-85. PubMed ID: 24936031
[TBL] [Abstract][Full Text] [Related]
14. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.
Chen Z; Guo J; Zhang K; Guo Y
Dis Markers; 2016; 2016():4639575. PubMed ID: 27239089
[TBL] [Abstract][Full Text] [Related]
15. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog.
Johnson AS; Couto CG; Weghorst CM
Carcinogenesis; 1998 Jan; 19(1):213-7. PubMed ID: 9472714
[TBL] [Abstract][Full Text] [Related]
16. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
17. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naïve primary osteosarcoma in dogs.
Ammons DT; Hopkins LS; Cronise KE; Kurihara J; Regan DP; Dow S
Commun Biol; 2024 Apr; 7(1):496. PubMed ID: 38658617
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.
Levine RA; Fleischli MA
Vet Pathol; 2000 Jan; 37(1):54-61. PubMed ID: 10643981
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B.
Karlsson EK; Sigurdsson S; Ivansson E; Thomas R; Elvers I; Wright J; Howald C; Tonomura N; Perloski M; Swofford R; Biagi T; Fryc S; Anderson N; Courtay-Cahen C; Youell L; Ricketts SL; Mandlebaum S; Rivera P; von Euler H; Kisseberth WC; London CA; Lander ES; Couto G; Comstock K; Starkey MP; Modiano JF; Breen M; Lindblad-Toh K
Genome Biol; 2013 Dec; 14(12):R132. PubMed ID: 24330828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
